Prognostic value of biomarkers in chronic heart failure with preserved left ventricular ejection fraction


Cite item

Full Text

Abstract

The paper reviews major biomarkers for determining the prognosis in patients with chronic heart failure and preserved ejection fraction. It also considers cystatin C, one of the novel and probably the most practically important biomarkers.

References

  1. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290(19):2581-2587. doi: 10.1001/jama.290.19.2581
  2. Brouwers FP, de Boer RA et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013;34(19):1424-1431. doi: 10.1093/eurheartj/eht066
  3. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New Engl J Med. 2006;355(3):251-259. doi: 10.1056/nejmoa052256
  4. Мареев В.Ю., Даниелян М.О., Беленков Ю.Н. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН. Сердечная недостаточность. 2006;7(4):164-171.
  5. Щербинина Е.В., Бажин Ю.В., Вайсберг А.Р. и др. Динамика этиологических причин формирования ХСН в репрезентативной выборке Нижегородской области за 9 лет наблюдения (1998—2007). Cердечная недостаточность: Всероссийская конференция ОССН. М.; 2007.
  6. Дикур О.Н., Полтавская М.Г., Гиверц И.Ю. и др. Желудочково-артериальное сопряжение при хронической сердечной недостаточности с сохраненной и сниженной фракцией выброса левого желудочка. Кардиология и сердечно-сосудистая хирургия. 2014;4:59-68.
  7. Fonarow GC. Epidemiology and risk stratification in acute heart failure. Am Heart J. 2008;155(2):200-207. doi: 10.1016/j.ahj.2006.10.043
  8. Gaggin HK, Januzzi JL Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta. 2013;1832 (12):2442-2450. doi: 10.1016/j.bbadis.2012.12.014
  9. Cea LB. Natriuretic peptide family: new aspects. Cur Med Chem-Cardiovasc Hematol Agents. 2005;3(2):87-98. doi:0.2174/1568016053544309
  10. Щекочихин Д.Ю., Копылов Ф.Ю., Козловская Н.Л., Сыркин А.Л. Кардиоренальный синдром при декомпенсированной сердечной недостаточности. Сердечная недостаточность. 2012;4:248-252.
  11. Iqbal N, Alim KS, Aramin H et al. Novel biomarkers for heart failure. Expert Rev Cardiovasc Ther. 2013;11(9):1155-1169. doi: 10.1586/14779072.2013.832476
  12. Maisel A, Mueller C, Nowak R et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55(19):2062-2076. doi: 10.1016/j.jacc.2010.02.025
  13. Anker DS, Auriccnio A, Bohm M et al. ESC Cuidelines for diagnosisand treatmentof acute and chronic heart failure. Eur Heart J. 2012;33(14):1787-1847. doi: 10.1093/eurheartj/ehs104
  14. Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC Jr. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol — Renal Physiol. 2003;284(5):F1115-F1119. doi: 10.1152/ajprenal.00337.2002
  15. van Veldhuisen DJ, Linssen GCM, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61(14):1498-1506. doi: 10.1016/j.jacc.2012.12.044
  16. Bongartz LG, Braam B, Verhaar MC et al. The nitric oxide donor molsidomine rescues cardiac function in rats with chronic kidney disease and cardiac dysfunction. AJP: Heart Circul Physiol. 2010;299(6):H2037-H2045. doi: 10.1152/ajpheart.00400.2010
  17. Kociol RD, Pang PS, Gheorghiade M et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56(14):1071-1078. doi: 10.1016/j.jacc.2010.06.016
  18. Steinberg BA, Zhao X, Heidenreich PA et al. Trends in patients hospitalaized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies and outcomes. Circulaition. 2012;126(1):65-75. doi: 10.1161/circulationaha.111.080770
  19. Соломахина Н.И. Систолическая и диастолическая хроническая сердечная недостаточность: особенности клиники и поражения миокарда, прогноз: Дис. ... д-ра мед. наук. М.; 2011. Ссылка активна на 30.06.2016. Доступно по: http://medical-diss.com/docreader/349870/d?#?page=1
  20. Sharma UC. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121-3128. doi: 10.1161/01.cir.0000147181.65298.4d
  21. Edelmann F, Holzendorf V, Wachter R et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail. 2014;17(2):214-223. doi: 10.1002/ejhf.203
  22. Jaarsma T, van Veldhuisen DJ. When, how and where should we «coach» patients with heart failure: the COACH results in perspective. Eur J Heart Fail. 2008;10(4):331-333. doi: 10.1016/j.ejheart.2008.02.017
  23. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCEF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):240-327. doi: 10.1161/cir.0b013e31829e8776
  24. Shimpo M et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186-2190. doi: 10.1161/01.cir.0000127958.21003.5a
  25. Manzano-Fernandez S, Mueller T, Pascual-Figal D et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107(2):259-267. doi: 10.1016/j.amjcard.2010.09.011
  26. Schmidt-Ott KM et al. Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia. Cur Opini Nephrol Hypertens. 2006;15(4):442-449. doi: 10.1097/01.mnh.0000232886.81142.58
  27. Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47(10):1987-1996. doi: 10.1016/j.jacc.2005.11.084
  28. Damman K, Masson S, Hillege HL et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011;32(21):2705-2712. doi: 10.1093/eurheartj/ehr190
  29. Ichimura T. Kidney injury molecule-1 (KIM-1), a putativeepithelial cell adhesion molecule containing a novel immunoglobulindomain, is up-regulated in renal cells after injury. J Biol Chem. 1998;273(7):4135-4142. doi: 10.1074/jbc.273.7.4135
  30. Jungbauer CG, Birner C, Jung B et al. Kidney injury molecule-1 and N-acetyl-b-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail. 2011;13(10):1104-1110. doi: 10.1093/eurjhf/hfr102
  31. Медицинские лабораторные технологии: руководство по клинической лабораторной диагностике. В 2 т. 3-е издание, переработанное и дополненное. Под ред. Карпищенко А.И. М.: ГЭОТАР-Медиа; 2013.
  32. Виллевальде С.В., Гудгалис Н.И., Исикова Х.В. и др. Роль цистатина С в оценке взаимосвязи функционального состояния почек и воспаления у больных артериальной гипертонией и диабетом 2-го типа. Клиническая фармакология и терапия. 2009;1:21-25.
  33. Croda-Todd MT, Soto-Montano XJ, Hernández-Cancino PA, Juárez- Aguilar E. Adult cystatin C reference intervals determined by nephelometric immunoassay. Clin Biochem. 2007;40(13-14):1084-1077. doi: 10.1016/j.clinbiochem.2007.05.011
  34. Sarnak MJ. Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults. Ann Int Med. 2005;142(7):497-505. doi: 10.7326/0003-4819-142-7-200504050-00008
  35. Tang WHW, van Lente F, Shrestha K et al. Impact of Myocardial Function on Cystatin C Measurements in Chronic Systolic Heart Failure. J Card Fail. 2008;14(5):394-399. doi: 10.1016/j.cardfail.2008.01.006
  36. Stewart GA, Gansevoort RT, Mark PB et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005;67(1):217-226. doi: 10.1111/j.1523-1755.2005.00072.x
  37. Carrasco-Sánchez FJ, Galisteo-Almeda L, Páez-Rubio I, Martínez-Marcos FJ, Camacho-Vázquez C, Ruiz-Frutos C, Pujol-De La Llave E. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail. 2011;17(1):31-38. doi: 10.1016/j.cardfail.2010.07.248

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies